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Objectives: In order to examine the reporting quality of urological RCTs, the initial objectives
of this study were to evaluate the degree to which RCTs involving urological surgical tech-
niques (as the intervention) published in the years 2000–2003 complied with the CONSORT
statement, and to assess trends and patterns of compliance. Following our initial findings
in urology, we extended the methodology to a number of other specialties to assess
whether our findings in urology could be generalised to other surgical disciplines.
Methods: The Royal Society of Medicine (RSM) Library was commissioned to search the
Medline and Cochrane databases for RCTs in compliance with the study inclusion criteria
below. Additional analyses of five other specialties (non-urological trials: cardiovascular,
gastrointestinal, hepatic, orthopaedic and vascular) were also made. For the non-urological
trials, 15 English language trials (from each specialty) were randomly picked from a blast
search conducted by the RSM for the year 2003.
The RCTs were given a score out of 22, reflecting how many of the 22 CONSORT items
were complied with (with each item being given equal weighting), this score was termed
the ‘‘CONSORT score’’.
Results: Urology trials: In total 122 RCT abstracts were identified which met the inclusion
criteria for this study. From these, 32 were excluded as they were follow-up studies, in-
volved a virtual procedure or were a cost analysis, leaving 90 RCTs published across 35 dif-
ferent journals which were analysed (68.2%, 90/122).
The average score of 11.1 for urological trials indicates that RCTs in our sample do not
comply with the CONSORT statement. No trials reported how they implemented their ran-
domisation process. Only 46% of RCTs stated that they had permission from an ethics re-
view board, 20% had declared their sources of funding, 14% stated whether there were any
conflicts of interest and only 1.1% stated their trial registry number. For non-urological
studies, an average CONSORT score of 11.2 was obtained.
Conclusion: Clinical research teams conducting RCTs in urology and other surgical disci-
plines demonstrate poor compliance with the CONSORT statement. We would recommend
that trials should be registered at their outset and that urological and other surgical jour-
nals to consider supporting the CONSORT statement and to have compliance ‘hard-wired’
into their submission, editorial and peer-review processes. Since it seems the best re-
searchers are unable to produce an RCT results which enable surgical techniques to be
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portance at all levels of surgical training.
We believe that an open debate is needed on the possible role of other research designs,
such as tracker studies. Whether this study actually raises the question of how appropriate
RCTs are to surgical techniques, we leave to the reader.
ª 2007 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
The importance of good medical research is paramount,
with billions invested by governments, private companies
and charities each year around the world. Today, universitylibraries pay $20,000 annually for some journals.1 As a conse-
quence, scientific publishing has now become a £7 billion in-
dustry with the market leader Elsevier becoming the fastest
riser in the FTSE 100 and making £1 billion in pre-tax profit in
2003.2 Medical research is now under greater scrutiny thanTable 1 – The CONSORT checklist of 22 items which RCTs should comply with8
Paper section
and topic
Item Description
Title and abstract 1 How participants were allocated to interventions (e.g., ‘‘random allocation’’, ‘‘randomized’’, or ‘‘randomly
assigned’’)?
Introduction
Background 2 Scientific background and explanation of rationale.
Methods
Participants 3 Eligibility criteria for participants and the settings and location where the data were collected.
Interventions 4 Precise details of the interventions intended for each group and how and when they
were actually administered.
Objectives 5 Specific objectives and hypotheses.
Outcomes 6 Clearly defined primary and secondary outcome measures and, when applicable,
any methods used to enhance the quality of measurements (e.g., multiple observations,
training of assessors).
Sample size 7 How sample size was determined and, when applicable, explanation of any interim
analyses and stopping rules?
Randomisation –
sequence generation
8 Method used to generate the random allocation sequence, including details of any
restriction (e.g., blocking, stratification).
Randomisation –
allocation concealment
9 Method used to implement the random allocation sequence (e.g., numbered containers
or central telephone), clarifying whether the sequence was concealed until interventions were assigned.
Randomisation –
implementation
10 Who generated the allocation sequence, who enrolled participants, and who assigned
participants to their groups?
Blinding (masking) 11 Whether participants, those administering the interventions, and those assessing the
outcomes were blinded to group assignment? How the success of blinding was evaluated?
Statistical methods 12 Statistical methods used to compare groups for primary outcome(s); methods for additional
analyses, such as subgroup analyses and adjusted analyses.
Results
Participant flow 13 Flow of participants through each stage (a diagram is strongly recommended). Specifically,
for each group report the numbers of participants randomly assigned, receiving intended
treatment, completing the study protocol, and analysed for the primary outcome. Describe protocol
deviations from study as planned, together with reasons?
Recruitment 14 Dates defining the periods of recruitment and follow-up.
Baseline data 15 Baseline demographic and clinical characteristics of each group.
Numbers analysed 16 Number of participants (denominator) in each group included in each analysis and whether
the analysis was by ‘‘intention-to-treat’’. State the results in absolute numbers when feasible
(e.g., 10/20, not 50%)?
Outcomes and estimation 17 For each primary and secondary outcome, a summary of results for each group, and the estimated
effect size and its precision (e.g., 95% confidence interval).
Ancillary analyses 18 Address multiplicity by reporting any other analyses performed, including subgroup analyses and
adjusted analyses, indicating those pre-specified and those exploratory.
Adverse events 19 All important adverse events or side effects in each intervention group.
Discussion
Interpretation 20 Interpretation of the results, taking into account study hypotheses, sources of potential bias
or imprecision and the dangers associated with multiplicity of analyses and outcomes.
Generalisability 21 Generalisability (external validity) of the trial findings.
Overall evidence 22 General interpretation of the results in the context of current evidence.
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but also due to well publicised cases of fraud.3 The ‘‘publish or
perish’’ culture prevalent in academic medicine, together with
the lack of consultation with statisticians, has been attributed
to what has been dubbed ‘‘the scandal of poor medical re-
search’’.4 There is a clear need to ensure that medical research,
especially that relating to clinical interventions, is carried out
and reported to the highest possible standards.
In the 1970s, the FDA in the United States of America,
passed mandate title 21, requiring an RCT before a drug can
be approved for sale. Today, randomised controlled trials are
widely accepted as the ‘‘gold standard’’ by which the benefit
of a pharmaceutical intervention is judged: their results affect
everything from bedside treatment decisions to national
healthcare policy. RCTs are classed as level 1b under the
Fig. 1 – The CONSORT flow diagram of progress through the
phases of an RCT.8‘‘levels of evidence’’ devised by Fletcher and Sackett over 20
years ago.5,6 The method used for treatment assignment is
crucial to clinical trial design. Random assignment has been
successfully used for over 55 years7 and is now the preferred
method for determining the merits of interventions.8
The prevention of selection and confounding bias are the
most important benefits of randomisation,9 and are crucial
components of RCTs.10 There are three main arguments for
these benefits11:
 Elimination of bias in the assignment of treatments – the se-
lection of a particular kind of person to receive a particular
kind of treatment is thus avoided.
 Random allocation facilitates blinding of the participants, in-
vestigators and evaluators. The use of a placebo has thus
been shown to reduce bias after treatment assignment.12
 Random assignment permits the use of probability theory –
to assess whether any difference in outcome merely reflects
chance.13
Inadequately reported RCTs are associated with bias in es-
timating the effectiveness of interventions.14,15 Despite a long
history, RCTs are still not being reported adequately, with a re-
cent review16 pointing out that only one in 122 RCTs of seroto-
nin use in depression described randomisation adequately.
Other reviews have criticised RCTs for low sample sizes, for
being too short, for poor blinding methods and for being
poorly reported.17,18
Poorly conducted trials represent a waste of time, effort
and funds. Also, poor quality reporting is associated with an
increased estimate of benefit for the intervention.17 Studies
reporting no exclusions appear less likely to have concealed
allocation.19 In addition, poorly reported RCTs have been asso-
ciated with poor methodology.20–22 Whatever the outcome of
a study, poor reporting clarity may make it difficult or impos-
sible for the average reader to interpret it. This in turn could
result in changes in clinical practice which are based on false
evidence and which may harm patients.
RCTs where a surgical procedure is the intervention pres-
ent their own difficulties. Perhaps the most obvious is that
a surgeon can almost never be blinded to the procedure that
he/she is performing, and one cannot usually blind a patient
Table 2 – Basic descriptors of the CONSORT score data
from the 90 RCTs analysed
Descriptor CONSORT scores
Range 6–18
Average 11.1
Standard deviation 2.4
Table 3 – The frequency of grouped CONSORT scores
CONSORT score (out of 22) Percentage frequency
5–7 4
8–10 35
11–13 39
14–16 9
17–19 3
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trolled studies also cause major problems of ethics, consent
and compliance, especially where patients may undergo an-
aesthesia but no operation.23 It may also be difficult to blind
the evaluator (certain clinical pictures and complications
tend to go with certain procedures). Cost and lack of funding
may be more difficult than in drug trials: very few surgical
techniques are linked to multinational pharmaceutical com-
panies. Other problems include recruitment and crossover
problems, differential placebo effects, type II errors, learning
curves, poor internal validity (comparing surgeon A with sur-
geon B), poor external validity (elite teams may be overrepre-
sented), low sample size leading to inadequately powered
studies, the logistics of investigating uncommon conditions
and emergency surgery. Some surgeons may even dislike ran-
domisation because of the ‘‘uncertainty’’ it creates.24–27 Over-
all, the potential for bias is far greater than trials of drugs
based interventions. A study by Solomon et al. of all general
surgical RCTs in 1990 found that the lowest quality trials
were those that had a surgeon as the principal author and
which assessed an actual surgical procedure (as opposed to
a drug being used in surgical patients). Despite these points,
nearly every report of a new surgical technique seems to finish
Table 4 – The CONSORT items in order of fulfillment
CONSORT item Fulfillment (%)
10 0 (0/90)
17 10.0 (9/90)
5 14.4 (13/90)
20 16.7 (15/90)
6 24.4 (22/90)
11 25.6 (23/90)
8 27.8 (25/90)
7 28.9 (26/90)
9 28.9 (26/90)
3 34.4 (31/90)
15 37.8 (34/90)
21 44.4 (40/90)
16 47.8 (43/90)
13 51.1 (46/90)
14 56.7 (51/99)
12 81.1 (73/90)
19 92.2 (83/90)
4 95.6 (86/90)
22 95.6 (86/90)
1 96.7 (87/90)
18 96.7 (87/90)
2 100.0 (90/90)
Table 5 – The percentage fulfillment of the three
additional items
Additional items Fulfillment (%)
Permission from
an ethics review board
46 (41/90)
Declaration of sources of funding 20 (22/90)
Stating the trial
registry number
1.1 (1/90)
Stating conflict
of interest
14 (13/90)with the recommendation that RCTs are needed. It thus seems
doubly important that surgical trials should be scrupulously
reported in order to allow interpretation of any potential bias.
Published in 199628 and revised in 2001,8 the CONSORT
statement aimed to improve the quality of parallel-group
RCTs through the creation of reporting standards. The state-
ment consists of a checklist of 22 essential items (Table 1 and
Fig. 1) that must be included in every RCT (along with an
accompanying flow diagram through the phases of an RCT).
To date, there have been no studies investigating the com-
pliance of surgical RCTs with CONSORT.
1.1. Objectives
In order to examine the reporting quality of urological RCTs,
the initial objectives of this study were to evaluate the degree
to which RCTs involving urological surgical techniques (as the
intervention) published in the years 2000–2003 complied with
the CONSORT statement, and to assess trends and patterns of
compliance. Following our initial findings in urology, we ex-
tended the methodology to a number of other specialties to
assess whether our findings in urology could be generalised
to other surgical disciplines.
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Fig. 3 – A line graph of the ‘frequency of fulfillment’ against
the CONSORT item.
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Search methods
The Royal Society of Medicine (RSM) Library was commissioned
to search the Medline and Cochrane databases for RCTs in com-
pliance with the study inclusion criteria below. Additional
analyses of five other specialties (non-urological trials: cardio-
vascular, gastrointestinal, hepatic, orthopaedic and vascular)
were also made. For the non-urological trials, 15 English lan-
guage trials (from each specialty) were randomly picked from
a blast search conducted by the RSM for the year 2003.
Inclusion criteria
Parallel-group RCTs in urology published in English language
journals in the years 2000–2003, involving a surgical procedure
being performed as at least one intervention were included.
Exclusion criteria
All observational and economic studies as well as short commu-
nications and non-patient RCTs were excluded. Studies where
the intervention was a pharmacological agent or device were
Table 6 – The geographical distribution of RCTs and their
average CONSORT scores
Country (main) Mean N Std. deviation
Sweden 14.5 2 0.7
Belgium 13.0 1 N/a
Denmark 13.0 1 N/a
Finland 13.0 2 0.0
UK 12.7 14 2.9
Canada 12.0 5 3.1
HK 12.0 1 N/a
Netherlands 12.0 2 1.4
Poland 12.0 1 N/a
USA 11.4 17 2.5
NZ 11.3 3 3.1
Greece 11.0 1 N/a
Pakistan 11.0 1 N/a
Taiwan 10.5 4 1.3
Germany 10.4 7 1.8
France 10.3 4 2.6
Austria 10.0 1 N/a
Thailand 10.0 1 N/a
Italy 9.6 5 1.3
Turkey 9.5 8 1.3
India 9.3 3 1.5
Egypt 9.0 1 N/a
Saudi Arabia 9.0 1 N/a
Brazil 8.5 2 2.1
Australia 8.0 2 2.8
N/a: Not applicable.
Table 7 – Mean CONSORT score by year of publication
Year Mean N Std. deviation
2000 11.3 18 2.9
2001 11.1 30 2.1
2002 10.7 20 2.1
2003 11.1 22 2.8
Total 11.1 90 2.4also excluded. RCTs involving virtual procedures were also
excluded.
Scoring
The RCTs were given a score out of 22, reflecting how many of
the 22 CONSORT items were complied with (with each item
being given equal weighting), this score was termed the ‘‘CON-
SORT score’’. Studies were given either a score of 1 or 0 for
each item within the CONSORT statement checklist.
We also assessed compliance with four items that do not
form part of the CONSORT statement but are generally recom-
mended for inclusion within an RCT report:
 Permission from an ethics review board,
 Declaration of sources of funding,
 Statement of the trial registry number,
 Declaration of any conflict of interest.
The initial scoring was performed by a professional statis-
tician (Derek Cooper). Twenty percent of the overall sample
was randomly selected and evaluated again separately by
one of the authors (RA) to check these scores and for inter-ob-
server error. In the event of disagreement, discussion would
take place with the senior co-author Gordon Muir until con-
cordance was reached. While provision was made for Delphi
panel assessment of any uncertain items following this path-
way, this was not needed in any case.
A number of sub-analyses were also conducted, including
the degree to which each CONSORT item was fulfilled across
the sample, as well as geographical and temporal trends in
compliance. The relationship between average CONSORT
score and the number of authors in the paper was analysed
as well as the way the conclusions of the study were phrased.
2. Results
2.1. Urology trials
In total122RCT abstractswere identifiedwhichmet the inclusion
criteria for this study. From these, 32 were excluded as they were
follow-up studies, involved a virtual procedure or were a cost
analysis, leaving 90 RCTs published across 35 different journals
Table 8 – The number of RCTs and average CONSORT
scores per author grouping
Authors Mean N Std. deviation
1 10.3 4 1.7
2 10.6 8 2.3
3 10.8 13 2.0
4 10.2 11 1.9
5 11.5 10 2.4
6 10.8 17 2.4
7 11.3 12 2.4
8 12.0 3 3.6
9 13.0 5 4.5
10þ 11.7 7 2.6
Total 11.1 90 2.4
Pearson’s correlation coefficient¼ 0.18 ( p¼ 0.095).
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citation reports 2003)
Journal 2003 impact
factor
Number of
studies
published
CONSORT
score
Acta Obstetricia et Gynecologica Scandinavica 1.166 1 13
American Journal of Obstetrics and Gynecology 2.518 3 13.3
Anaesthesia 2.041 1 9
BJU International 1.642 6 11.5
BMJ 7.209 1 12
British Journal of Obstetrics & Gynaecology No impact factor 1 11
Clinical Nephrology 1.341 1 13
Clinical Transplantation 1.582 2 7.5
European Urology 2.247 3 11
Hong Kong Medical Journal No impact factor 1 12
International Urogynecology Journal 1.911 1 10
The Journal of the American Association of
Gynecologic Laparoscopists
1.371 1 9
Journal of Health Services Research & Policy No impact factor 1 14
Journal of the Medical Association of Thailand No impact factor 1 10
Journal of the College of Physicians and
Surgeons-Pakistan
No impact factor 1 11
Journal of Endourology 1.262 8 9
Journal of Family Planning & Reproductive
Health Care
No impact factor 1 7
Journal of Infectious Diseases 4.481 1 16
Journal of the American Association of
Gynelogic Laparoscopists
1.371 1 9
Journal of Urology 3.297 26 11.4
Kidney International 5.302 2 12.5
Lancet 18.316 3 14
Minerva Chirurgica No impact factor 1 8
The New England Journal of Medicine 34.833 1 15
Neurourology and Urodynamics 2.927 1 12
Obstetrics and Gynecology 2.957 1 11
Pediatric Nephrology 1.219 1 12
Pediatric Surgery International 0.562 1 6
Scandinavian Journal of Urology and Nephrology No impact factor 1 10
Scandinavian Journal of Urology and Nephrology 0.612 1 13
Transplant International 1.204 1 8
Transplantation 3.608 2 12
Urologia Internationalis 0.525 3 11
Urologic Nursing No impact factor 1 8
Urology 2.782 8 10.8which were analysed (68.2%, 90/122). Some raw data on the
CONSORT scores are shown in Tables 2–5 and Figs. 2 and 3.
2.2. Additional criteria
Urological RCTs were conducted in 25 countries during 2000–
2003 (Table 6).
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Fig. 4 – A graph of CONSORT score against impact factor.
Pearson’s correlation coefficient[ 0.35.Over the period studied 2000–2003, there was no significant
difference in the average CONSORT score (Tables 7 and 8 –
online only).
The RCTs were published in 35 Medline indexed journals
(Table 9 and Fig. 4).
Cardiovascular, gastrointestinal, hepatic, orthopaedic and
vascular trials are shown in Tables 10–12 and Fig. 5.
Table 10 – Basic descriptors of the CONSORT score data
from the 74 non-urology RCTs analysed
Group N Mean Range Std. deviation
Cardiovascular 15 10.3 7–16 2.3
Gastrointestinal 15 10.9 7–16 2.2
Hepatic 15 11.9 9–15 1.8
Orthopaedic 14 10.8 4–18 3.5
Vascular 15 12.0 6–20 3.4
Average 74 11.2 4–20 2.7
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Criteria Cardiovascular
(%)
Gastrointestinal
(%)
Hepatic
(%)
Orthopaedic
(%)
Vascular
(%)
Total
(%)
Permission from an ethics review board 93.3 60.0 40.0 64.3 53.3 62.2 (46/74)
Declaration of sources of funding 60.0 20.0 6.7 28.6 26.7 28.4 (21/74)
Stating the trial registry number 0 0 0 0 0 0 (0/75)
Stating conflict of interest 20.0 0.0 13.3 35.7 20.0 17.6 (13/74)
Table 12 – A table comparing impact factors with CONSORT scores (impact factors obtained from Thomson ISI journal
citation reports 2003)
Journal Impact factor
of journal
Number of
studies
published
Average
CONSORT
score
Acta Chirurgica Belgica No impact factor 1 10
Acta Orthopaedica Scandinavica 0.77 1 11
American Journal of Roentgenology No impact factor 1 9
American Heart Journal 3.3 1 8
American Journal of Sports Medicine 2.063 1 13
American Journal of Surgery 2.183 1 11
Angiology 0.912 1 13
The Annals of Thoracic Surgery 2.041 5 8.8
Annals of Surgery 5.937 6 12.5
Archives of Surgery 2.753 1 12
Archives of Medical Research 1.277 1 11
Brazilian Journal of Medical and Biological Research 0.74 1 13
British Journal of Surgery 3.772 2 12.5
Cardiovascular and Interventional Radiology 1.207 1 10
Catheterization & Cardiovascular Interventions 1.519 1 14
Circulation 11.164 4 10.8
Clinical Orthopaedics and Related Research 1.357 3 10
Colorectal Disease ? 2 8
Current Surgery ? 1 10
Diseasea of the Colon and Rectum 2.343 2 9
Diseases of the Esophagus 0.809 1 11
European Spine Journal 1.527 1 13
European Journal of Cadiothoracic Surgery 1.465 1 12
Gastrointestinal Endoscopy 3.328 2 14.5
Gut 5.883 1 14
Heart 3.16 1 16
Journal of Nippon Medical School ? 1 11
Journal of Vascular Surgery 3.507 1 16
Journal of American College of Cardiology 7.599 4 13.5
Journal of Bone & Joint Surgery (British) 1.503 1 11
Journal of Bone & Joint Surgery (American) 1.921 1 15
Journal of Hand Surgery (British-European) 0.562 1 10
Journal of Orthopaedic Surgery ? 1 9
Journal of Spinal Disorders & Techniques 0.736 2 5
Journal of Vascular Surgery 3.507 1 13
Lasers in Surgery & Medicine 2.565 1 11
Obesity Surgery 2.421 1 11
Revista do Hospital das Clı´nicas ? 1 10
Romanian Journal of Gastroenterology ? 1 9
Scandinavian Cardiovascular Journal 0.573 1 11
Spine 2.676 2 14.5
Stroke 5.233 1 8
Surgical Endoscopy 2.122 3 11
Surgery 2.611 2 11.5
Surgical Endoscopy 2.122 1 10
Techniques of Coloproctology ? 1 12
The Heart Surgery Forum 0.897 1 11
World Journal of Gastroenterology 3.318 1 10
?¼ impact factor not determined/found.
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The average score of 11.1 for urological trials indicates that
RCTs in our sample do not comply with the CONSORT state-
ment. The broad range of scores (6–18) and the standard devi-
ation suggest a high degree of variability in compliance,
additionally no trial scored 22. These figures were lower
than we had expected, which was the reason we decided to as-
sess other surgical specialties to exclude the possibility of
urology being an outlier of poor quality when reporting
RCTs. However, the five other specialties examined, showed
similar mean CONSORT scores and ranges (averaging 11.2
and 4–20). This suggests that poor reporting of RCTs is ubiqui-
tous in surgical disciplines. Moreover, it suggests that our
comments relating to urological surgical trials can be general-
ised to other specialties.
It has previously been reported that poorly reported RCTs
are associated with bias in estimating the effectiveness of in-
terventions.14,15 Some have stated that poor quality statistical
analyses are the major reason for poor reporting.4,29,30 How-
ever, in this study, omission of statistical methods or the use
of inappropriate statistical techniques was only the 16th
most common reporting error for urological trials (see Table 4).
Of greater concern is that not one urological trial described how
their process of randomisation was achieved. This is a critical
omission, as the very essence of an RCT is the process of ran-
domisation, particularly when the trial may not be blinded
and potential conflicts of interests are often not declared.
All 22 items of the CONSORT statement are essential, not
optional, so even a score of 18 out of 22 (the top score within
the urological cohort) represents misses four ‘‘essential’’ items.
The additional criteria we specified were also poorly fulfilled,
with only 14% stating whether there is a conflict of interest.
Poor quality reporting in RCTs compounds poor methodology
and has a knock-on effect for meta-analyses and systematic
reviews.29,30
A search of the CONSORT statement’s website31 showed
that no urological journals formally support the CONSORT
statement and only 13 surgical journals but no surgical associ-
ations support the statement. Overall, the CONSORT state-
ment is supported by over 200 journals and by over 30 major
health organisations around the world.31 Hence, awareness
of the CONSORT statement among surgical journals and asso-
ciations may be poor.
The USA hosted the most RCTs (17) with the UK coming
second (14) and Turkey third (8). Turkey has a much greater
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Fig. 5 – A graph of CONSORT score against impact factor
for non-urology studies. Pearson’s correlation
coefficient[ 0.17.output of urological RCTs than expected from its overall re-
search and citation output; this may reflect a particular inter-
est in urology. Overall, these results (Table 6) differ
significantly from the 20-year research citation history of
these countries (Fig. 6).32 Importantly, the number of trials
published by a country did not correlate with the average
CONSORT of those trials, with Sweden coming top, having
a mean score of 14.5 (n¼ 2, Std. deviation¼ 0.7).
There was no improvement in the CONSORT score over
time implying that reporting standards are not improving
and CONSORT is not being widely implemented. Greater qual-
ity controls in reporting by both the institution and as part of
the criteria for gaining funding could help to tackle this issue
in coming years. More journals should consider accepting the
principles of CONSORT into their instructions to authors and
editorial policies.
There was a slight trend towards improving CONSORT
scores with an increase in the number of authors involved
in the study; however, this did not achieve significance
( p¼ 0.095). There was also a slight trend towards increasing
CONSORT scores with an increase in the impact factor of the
journal in which it was published, but this was not significant
for either urological or non-urological trials (Pearson’s correla-
tion coefficient of 0.35 and 0.17, respectively). Importantly,
this suggests that impact factor is not a quality indicator for
RCTs published in a particular journal.
Our study does have a number of important limitations.
Firstly, only RCTs published in English language journals
indexed in Medline were included. Also, we do not know
how much papers were ‘‘improved’’ by the journal editors
and peer-reviewers after submission to the journal (and this
may vary from journal to journal depending on their re-
viewers and editors). We have not analysed those trials that
were rejected for publication (although these, being of
‘‘unpublishable’’ quality might well have scored even lower).
Surgeons face formidable difficulties in conducting RCTs.
Problems with blinding, standardising procedures, controlling
for bias, the effect of learning curves, difficulties in recruit-
ment and the personal characteristics of surgeons themselves
are well documented.34,24 However, our data support the view
that surgical trials are not just difficult to perform, but are
poorly reported as well. It would be easy to assume that this
apparently poor reporting is a function of ignorance of the
CONSORT statement, inability to conduct a proper RCT, or in-
tellectual laziness. However, it can reasonably be assumed
Fig. 6 – Number of world citations of scientific publications
per country, 1981–2000, taken from the office of science
and technology.33
i n t e rn a t i o n a l j o u rn a l o f s u r g e r y 5 ( 2 0 0 7 ) 4 1 3 – 4 2 2 421that those papers assessed represent the output from many of
the world’s best surgical researchers in the areas analysed.
We also know from personal communication that many of
the research groups represented have contributed to mulit-
centre pharmaceutical RCTs, so the authors must have some
familiarity with rigorous RCT design. Poor compliance with
CONSORT rests not only with authors, but also with editors
of journals and trial sponsors too who should insist on its
implementation for the trial report.
Clinical research teams conducting RCTs in urology and
other surgical disciplines demonstrate poor compliance with
the CONSORT statement. We would recommend that trials
should be registered at their outset and that urological and
other surgical journals to consider supporting the CONSORT
statement and to have compliance ‘hard-wired’ into their sub-
mission, editorial and peer-review processes. Since it seems
the best researchers are unable to produce an RCT results
which enable surgical techniques to be critically assessed,
there is a need for education about the CONSORT statement
and its importance at all levels of surgical training.
We believe that an open debate is needed on the possible
role of other research designs, such as tracker studies.35
Whether this study actually raises the question of how appro-
priate RCTs are to surgical techniques, we leave to the reader.
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Appendix.
GHM modification of CONSORT scoring
CONSORT scoring criteria
CONSORT score 1 – This was scored if a word with ‘random’ in
its root was included in the title or abstract.
CONSORT score 2 – If some background was provided, how-
ever brief, this was scored. We did not attempt to judge the
‘‘quality’’ of explanations.
CONSORT score 3 – This was scored only if some details of el-
igibility or exclusion criteria were included and the settings/
location where the data was collected was mentioned.
CONSORT score 4 – If some details of the interventions were
included this was scored. We did not attempt to judge the
quality of the information offered.
CONSORT score 5 – This was scored if we considered that both
hypotheses and objectives were clearly stated.
CONSORT score 6 – Scored if outcome measures are defined.
Methods to enhance the quality of measurements were ig-
nored because if such methods were not described we could
not know if they were used.
CONSORT score 7 – Scored if indication given regarding calcu-
lation of sample size. If interim analyses were specified then
stopping rules were also required.CONSORT score 8 – Scored if the method used to generate the
random sequence was stated. Unless restrictions explicitly
stated we could not know whether they had been used.
CONSORT score 9 – Scored if method of implementing random
allocation sequence stated.
CONSORT score 10 – Scored if all who generated the allocation
sequence, who enrolled participants, and who assigned par-
ticipants to their groups stated.
CONSORT score 11 – Blinding is not possible for many surgical
studies, but we felt some acknowledgment of the issue should
have been made. Scored if there is some mention of blinding
whether or not it could be implemented in any sense.
CONSORT score 12 – Scored if statistical methods for all
reported comparisons were mentioned.
CONSORT score 13 – Scored if the flow of all participants was
clear (a flow diagram was not necessary) and whether details
of protocol deviations are given for the deviations were men-
tioned. If no deviations were mentioned we assumed there
were none and, therefore, this CONSORT item was not vio-
lated. Of course, we could not know if all protocol deviations
were reported.
CONSORT score 14 – Scored if starting date was given with
some indication of length of study.
CONSORT score 15 – Scored if baseline demographic and clin-
ical characteristics of each group were given, but if signifi-
cance tests were reported between the groups this CONSORT
item was considered violated and not scored.
CONSORT score 16 – Scored if we considered it clear how
many participants were included in each analysis and the
‘intention-to-treat’ criteria satisfied. We considered that the
‘intention-to-treat’ criteria were satisfied if there were no
protocol violations or if ‘intention-to-treat’ was mentioned.
CONSORT score 17 – Scored if for each primary and secondary
outcome there was a summary of results for each group in-
cluding the estimated effect size and its precision.
CONSORT score 18 – If, as was usually the case, other analyses
were not reported we could not tell whether this CONSORT
item had been violated.
CONSORT score 19 – Scored if important adverse events or
side effects in each intervention group were mentioned. If
there were no adverse effects a statement to that effect was
required before this item was scored.
CONSORT score 20 – Scored if there was some interpretation
of results offered (we do not judge the quality of this) and if
some identification of possible study weaknesses was men-
tioned. Not scored if the authors interpreted a non-significant
result as indicating equivalence of interventions.
CONSORT score 21 – Scored if the authors attempted to gener-
alise the results.
CONSORT score 22 – Scored if the authors attempted to inter-
pret their results in the context of current evidence.
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